Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 354

1.

Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma.

Maeda T, Kanzaki H, Chiba T, Ao J, Kanayama K, Maruta S, Kusakabe Y, Saito T, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Ooka Y, Nakamoto S, Nakagawa R, Muroyama R, Kanda T, Maruyama H, Kato N.

BMC Cancer. 2019 Nov 12;19(1):1088. doi: 10.1186/s12885-019-6322-9.

2.

Superinfection of hepatitis A virus in hepatocytes infected with hepatitis B virus.

Win NN, Kanda T, Ogawa M, Nakamoto S, Haga Y, Sasaki R, Nakamura M, Wu S, Matsumoto N, Matsuoka S, Kato N, Shirasawa H, Yokosuka O, Okamoto H, Moriyama M.

Int J Med Sci. 2019 Sep 20;16(10):1366-1370. doi: 10.7150/ijms.32795. eCollection 2019.

3.

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.

Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Kadir Dokmeci A, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Ooka Y, Yokosuka O, Sarin SK, Omata M.

Hepatol Int. 2019 Nov;13(6):649-661. doi: 10.1007/s12072-019-09988-7. Epub 2019 Sep 20.

4.

Are direct-acting antivirals against hepatitis C virus infection not associated with the recurrence of hepatocellular carcinoma?

Ogawa M, Kanda T, Moriyama M.

Hepatobiliary Surg Nutr. 2019 Aug;8(4):423-425. doi: 10.21037/hbsn.2019.03.19. No abstract available.

5.

Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma.

Midorikawa Y, Takayama T, Nakayama H, Higaki T, Moriguchi M, Moriya K, Kanda T, Matsuoka S, Moriyama M.

BMC Gastroenterol. 2019 Aug 19;19(1):147. doi: 10.1186/s12876-019-1069-y.

6.

Long-Term Trends in Respiratory Function After Esophagectomy for Esophageal Cancer.

Otani T, Ichikawa H, Hanyu T, Ishikawa T, Kano Y, Kanda T, Kosugi SI, Wakai T.

J Surg Res. 2020 Jan;245:168-178. doi: 10.1016/j.jss.2019.07.040. Epub 2019 Aug 14.

PMID:
31421359
7.

Prognostic four-gene signature for overall survival in patients with hepatocellular carcinoma.

Kanda T, Yokosuka O, Moriyama M.

Hepatol Int. 2019 Sep;13(5):519-520. doi: 10.1007/s12072-019-09976-x. Epub 2019 Aug 16. No abstract available.

PMID:
31420806
8.

Possible association of arrestin domain-containing protein 3 and progression of non-alcoholic fatty liver disease.

Ogawa M, Kanda T, Higuchi T, Takahashi H, Kaneko T, Matsumoto N, Nirei K, Yamagami H, Matsuoka S, Kuroda K, Moriyama M.

Int J Med Sci. 2019 Jun 2;16(7):909-921. doi: 10.7150/ijms.34245. eCollection 2019.

9.

Follow-up Results of HCV GT2 Patients After Sofosbuvir/Ribavirin Therapy: Careful Attention to Occurrence of HCC.

Kaneko T, Kanda T, Nirei K, Matsumoto N, Yamazaki M, Shibata T, Tamura A, Ogawa M, Nakajima N, Matsuoka S, Kuroda K, Komoriya T, Yamamoto T, Takayama T, Moriyama M.

Anticancer Res. 2019 Jul;39(7):3855-3862. doi: 10.21873/anticanres.13535.

PMID:
31262913
10.

Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.

Ogasawara S, Ooka Y, Itokawa N, Inoue M, Okabe S, Seki A, Haga Y, Obu M, Atsukawa M, Itobayashi E, Mizumoto H, Sugiura N, Azemoto R, Kanayama K, Kanzaki H, Maruta S, Maeda T, Kusakabe Y, Yokoyama M, Kobayashi K, Kiyono S, Nakamura M, Saito T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N.

Invest New Drugs. 2019 Jun 6. doi: 10.1007/s10637-019-00801-8. [Epub ahead of print]

PMID:
31172442
11.

Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world.

Nishida T, Sakai Y, Takagi M, Ozaka M, Kitagawa Y, Kurokawa Y, Masuzawa T, Naito Y, Kagimura T, Hirota S; members of the STAR ReGISTry Study Group.

Gastric Cancer. 2020 Jan;23(1):118-125. doi: 10.1007/s10120-019-00966-4. Epub 2019 Apr 30.

12.

Palliative interventions for patients with incurable locally advanced or metastatic thoracic esophageal carcinoma.

Kakuta T, Kosugi SI, Ichikawa H, Hanyu T, Ishikawa T, Kanda T, Wakai T.

Esophagus. 2019 Jul;16(3):278-284. doi: 10.1007/s10388-019-00665-0. Epub 2019 Apr 4.

PMID:
30949884
13.

Exosomes and Hepatocellular Carcinoma: From Bench to Bedside.

Sasaki R, Kanda T, Yokosuka O, Kato N, Matsuoka S, Moriyama M.

Int J Mol Sci. 2019 Mar 20;20(6). pii: E1406. doi: 10.3390/ijms20061406. Review.

14.

Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review.

Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M.

Int J Mol Sci. 2019 Mar 18;20(6). pii: E1358. doi: 10.3390/ijms20061358. Review.

15.

POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33.

Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, Aiba Y, Nakamura H, Kouno H, Kouno H, Ohta H, Sugi K, Nikami T, Yamashita T, Katsushima S, Komeda T, Ario K, Naganuma A, Shimada M, Hirashima N, Yoshizawa K, Makita F, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Yamashita H, Matsushita K, Tsunematsu S, Yabuuchi I, Nishimura H, Shimada Y, Yamauchi K, Komatsu T, Sugimoto R, Sakai H, Mita E, Koda M, Nakamura Y, Kamitsukasa H, Sato T, Nakamuta M, Masaki N, Takikawa H, Tanaka A, Ohira H, Zeniya M, Abe M, Kaneko S, Honda M, Arai K, Arinaga-Hino T, Hashimoto E, Taniai M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Takaki A, Yamagiwa S, Seike M, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Ebinuma H, Himoto T, Murata K, Shimoda S, Nagaoka S, Abiru S, Komori A, Migita K, Ito M, Yatsuhashi H, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M.

Sci Rep. 2019 Jan 14;9(1):102. doi: 10.1038/s41598-018-36490-1.

16.

Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response.

Sasaki R, Kanda T, Kato N, Yokosuka O, Moriyama M.

World J Hepatol. 2018 Dec 27;10(12):898-906. doi: 10.4254/wjh.v10.i12.898.

17.

APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?

Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Yokosuka O, Sarin SK, Omata M.

Hepatol Int. 2019 Mar;13(2):103-109. doi: 10.1007/s12072-018-9915-5. Epub 2018 Dec 11.

18.

Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.

Ooka Y, Miho K, Shuntaro O, Nakamura M, Ogasawara S, Suzuki E, Yasui S, Chiba T, Arai M, Kanda T, Maruyama H, Yokosuka O, Kato N, Mochizuki H, Omata M.

Hepatol Int. 2018 Nov;12(6):523-530. doi: 10.1007/s12072-018-9895-5. Epub 2018 Sep 21.

PMID:
30242733
19.

Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.

Takehara T, Sakamoto N, Nishiguchi S, Ikeda F, Tatsumi T, Ueno Y, Yatsuhashi H, Takikawa Y, Kanda T, Sakamoto M, Tamori A, Mita E, Chayama K, Zhang G, De-Oertel S, Dvory-Sobol H, Matsuda T, Stamm LM, Brainard DM, Tanaka Y, Kurosaki M.

J Gastroenterol. 2019 Jan;54(1):87-95. doi: 10.1007/s00535-018-1503-x. Epub 2018 Sep 10.

20.

Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.

Sasaki R, Meyer K, Moriyama M, Kato N, Yokosuka O, Ray RB, Aurora R, Ray R, Kanda T.

J Med Virol. 2019 Mar;91(3):411-418. doi: 10.1002/jmv.25310. Epub 2018 Oct 28.

PMID:
30192392

Supplemental Content

Loading ...
Support Center